Riskpilot← Back to searchSign inGet full accessDICO AS
ASActiveOrg 985691088Strandveien 55, 1366 LysakerWholesale of pharmaceutical and medical goods · NACE 4646Est. 20037 employeeswww.dico.no
Revenue 2025
NOK 109,8M
+26% vs 2024
EBITDA margin
29.6%
+90% vs 2024
Equity ratio
69.9%
Financial strength
Net profit 2025
NOK 26,1M
+88% vs 2024
| Revenue | NOK 109,8M | +26% |
| EBITDA | NOK 32,5M | +90% |
| Net profit | NOK 26,1M | +88% |
| Total assets | NOK 58,8M | +3% |
| Equity | NOK 41,1M | +60% |
| Employees | 7 | — |
Legal name
DICO AS
Org number
985691088
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
5. juni 2003
Share capital
NOK 1 235 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Utvikling og salg av forbruksmateriell og maskiner, samt konsulenttjenester, service, innstallasjon og annen beslektet virksomhet. I hovedsakelig for helse-, kosmetikk- og industrimarkedet.
Address
Strandveien 55, 1366 Lysaker
Website
www.dico.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15 584 | 17 024 | 10 062 | 16 081 | 21 741 | 37 407 | 37 515 | 37 634 | 38 976 | 43 647 | 39 498 | 35 924 | 41 037 | 49 001 | 56 546 | 49 905 | 87 305 | 109 757 |
| Staff expenses | −1 448 | −2 133 | −2 478 | −2 577 | −3 234 | −5 017 | −9 928 | −7 456 | −5 805 | −5 939 | −6 674 | −6 165 | −5 740 | −8 899 | −7 261 | −8 739 | −10 447 | −10 880 |
| EBITDA | 1 704 | 2 679 | 38 | 3 146 | 3 603 | 4 117 | 4 716 | 6 718 | 5 135 | 4 479 | 5 401 | 4 447 | 2 983 | 9 676 | 13 896 | 4 871 | 17 124 | 32 472 |
| Depreciation & amort. | −461 | −488 | −485 | −466 | −374 | −491 | −443 | −413 | −436 | −526 | −331 | −219 | −266 | −247 | −216 | −209 | −197 | −178 |
| EBIT | 1 244 | 2 191 | −448 | 2 680 | 3 229 | 3 626 | 4 273 | 6 305 | 4 700 | 3 953 | 5 070 | 4 228 | 2 717 | 9 429 | 13 680 | 4 662 | 16 927 | 32 294 |
| Net financials | −192 | −84 | −78 | −88 | −98 | −64 | −31 | 39 | −47 | −179 | −366 | −301 | −103 | −117 | 12 | 199 | 753 | 1 145 |
| Profit before tax | 1 052 | 2 107 | −526 | 2 593 | 3 131 | 3 562 | 4 242 | 6 344 | 4 653 | 3 774 | 4 704 | 3 927 | 2 614 | 9 312 | 13 692 | 4 861 | 17 680 | 33 439 |
| Tax | 297 | 590 | −204 | 726 | 876 | 1 007 | 1 146 | 1 725 | 1 169 | 920 | 1 097 | 864 | 574 | 2 049 | 3 020 | 1 072 | 3 790 | 7 369 |
| Net profit | 755 | 1 517 | −322 | 1 867 | 2 255 | 2 555 | 3 096 | 4 619 | 3 483 | 2 853 | 3 607 | 3 064 | 2 039 | 7 263 | 10 671 | 3 789 | 13 889 | 26 070 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6 250 | 6 766 | 7 989 | 13 576 | 17 704 | 21 414 | 30 359 | 22 396 | 19 268 | 37 516 | 17 426 | 23 551 | 30 279 | 38 450 | 30 168 | 29 689 | 57 070 | 58 843 |
| Equity | 2 849 | 4 367 | 3 045 | 3 912 | 4 167 | 6 721 | 10 545 | 9 789 | 5 873 | 6 056 | 6 563 | 7 627 | 7 666 | 7 930 | 8 001 | 11 790 | 25 679 | 41 123 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 863 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 401 | 2 399 | 4 945 | 9 664 | 13 537 | 14 693 | 19 813 | 12 607 | 13 395 | 15 598 | 10 863 | 15 924 | 22 613 | 30 521 | 22 167 | 17 899 | 31 390 | 17 720 |
| Total debt | 3 401 | 2 399 | 4 945 | 9 664 | 13 537 | 14 693 | 19 813 | 12 607 | 13 395 | 31 460 | 10 863 | 15 924 | 22 613 | 30 521 | 22 167 | 17 899 | 31 390 | 17 720 |
EBITDA margin
29.6%
This company
15.8%
Market median
+87% vs market
20082025
Equity ratio
69.9%
This company
38.2%
Market median
+83% vs market
20082025
Return on equity
63.4%
This company
18.4%
Market median
+245% vs market
20082025
Net profit margin
23.8%
This company
8.1%
Market median
+194% vs market
20082025
Asset turnover
1.87×
This company
1.12×
Market median
+67% vs market
20082025
Debt / equity
0.43×
This company
0.62×
Market median
+31% vs market
20082025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ØR Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
BV Chief Executive Officer | Chief Executive Officer | 2003 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Onemed As | Company | 95.0% | 95.0% | 2024 |
Infuture Invest As | Company | 81.0% | 81.0% | 2022 |
Fundingsrud Holding As | Company | 9.0% | 9.0% | 2022 |
Anjos As | Company | 5.0% | 5.0% | 2022 |
Dico As | Company | 5.0% | 5.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fundingsrud Holding As
DICO AS Board members of DICO AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øyvind Rustand Dahl | Chief Executive Officer | 0 companies |
| Bård Vegard Marken | Chief Executive Officer | 0 companies |
| Lasse Fundingsrud Bydal | Board of Directors | 0 companies |
| Jan Knoph | Chairman | 0 companies |
| Robert Andrzej Kolakowski | Board of Directors | 0 companies |
| Morten Dahl | Chairman | 0 companies |
| Jens Ole Ørneberg | Board of Directors | 0 companies |